• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clarient Diagnostics Services Receives Accreditation From College of American Pathologists and Moves Into New Laboratory Facility

Posted on: Wednesday, 18 January 2006, 09:01 CST

ALISO VIEJO, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, announced that they have moved their Diagnostics Services laboratory to a new expanded facility in Aliso Viejo, California. In addition, the lab has been awarded accreditation by the Commission on Laboratory Accreditation of the College of American Pathologists (CAP), based on the results of a recent on-site inspection.

Clarient's move was motivated in part by capacity constraints at Clarient's former facility, and Clarient expects that the new laboratory facility will enable it to efficiently scale its laboratory operations to meet the growing demand for its services.

Clarient President and CEO, Ronald A. Andrews, Jr. said, "This move represents the achievement of a key milestone in our growth strategy. This state-of-the-art facility will allow us to use our current resources more efficiently, provide increased capacity to achieve the growth expected over the coming years, and add new technologies for advanced cancer assessment as they become available. In addition, we will be able to accommodate our expanding work with biopharmaceutical companies as we develop emerging applications utilizing our ACIS technology, where we continue to be a leader in rare event detection. Finally, in the near future we also plan to move the remainder of our operations, which includes administration and our Instrument Systems division, to this one consolidated corporate site."

After receiving the CAP accreditation, Clarient's Medical Director, Kenneth J. Bloom, M.D. said, "Our team is very proud to have received national recognition by this esteemed organization. It acknowledges the importance that we place on exceeding the highest quality standards by providing our pathology customers -- and their physician clients -- with the best possible test results." The CAP Laboratory Accreditation Program, begun in the early 1960s, is recognized by the federal government as being equal to or more stringent than the government's own inspection program.

About Clarient Inc.

Clarient provides market leading technologies, services and expert support for the characterization, assessment and treatment of cancer, leading to more accurate diagnoses by pathologists, more confident treatment decisions by oncologists, a more efficient way to identify and develop pharmaceuticals and, ultimately, better outcomes for patients. A majority-owned subsidiary of Safeguard Scientifics, Inc., Clarient was formed in 1996 to develop and market the Automated Cellular Imaging System (ACIS). This digital imaging and assessment system allowed pathologists, for the first time, to obtain potentially more reliable, reproducible quantitative results for a broad range of slide-based diagnostic tests. In 2005, the ACIS and other leading diagnostic technologies such as flow cytometry and genetic testing were brought in-house to a state-of-the-art diagnostic laboratory and surrounded by a team of premiere cancer specialists, forming the Clarient Diagnostic Services business. This facility and the Clarient team support the efforts of pathologists and the biopharmaceutical industry as a central resource for cancer diagnostics, disease interpretation, remote pathology, and contract research operations.

Clarient's mission is to provide critical information to clinicians that will improve the quality and reduce the cost of patient care, and speed drug discovery. Many of the top clinical laboratories, hospitals, university medical centers and biopharmaceutical companies in the United States and Europe are currently using Clarient technology and services. Clarient and ACIS are registered trademarks of Clarient. For more information, visit http://www.clarientinc.com/.

About Safeguard

Safeguard Scientifics, Inc. advances the value of revenue- stage information technology and life sciences companies. Safeguard provides growth capital as well as a range of strategic, operating and management resources to help its partner companies build value in their businesses. The company participates in expansion financings, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard, please visit http://www.safeguard.com/.

The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to the Company's ability to successfully commence providing diagnostic laboratory services at its new location and to grow its laboratory services business, the Company's ability to successfully move its other operations to the new facility, the Company's ability to obtain additional financing on acceptable terms or at all, the Company's ability to continue to develop and expand its instrument systems business and its diagnostic laboratory services business, the performance and acceptance of the Company's system in the market place, the success of the Company's development and distribution arrangement with DAKO, the Company's ability to expand and maintain a successful sales and marketing organization, continuation of favorable third party payer reimbursement for tests performed using the Company's system, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in developing any new software applications, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in cell imaging and dependence on third parties for collaboration in developing new tests and in distributing the Company's systems and tests performed on the system, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to instrument placements, new contracts for placements, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Roberta L. Smigel Clarient, Inc. (949) 276.0110 investorrelations@clarientinc.com

Clarient, Inc.

CONTACT: Roberta L. Smigel of Clarient, Inc., +1-949-276-0110,investorrelations@clarientinc.com

Web site: http://www.clarientinc.com/http://www.safeguard.com/

Source: PRNewswire-FirstCall

More News in this Category